Sign In
30 Apr 2019 15:15
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director Dealing
London, April 30, 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 29 April 2019, Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma, purchased 6000 American Depositary Shares (ADSs) at a total price of USD5.887 per ADS.
In addition, Richard Jones, Chief Financial Officer of Mereo BioPharma, purchased 2025 American Depositary Shares (ADSs) at a price of USD6.04 per ADS.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 | Details of the person discharging managerial responsibilities | |||||
a) | Name | Denise Scots-Knight | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc | ||||
b) | LEI | 213800U8JQHIJOS5AS09 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)
| ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 6000 Aggregated price: USD5.887 | ||||
e) | Date of the transaction | 2019-04-29 | ||||
f) | Place of the transaction | XNMS | ||||
1 | Details of the person discharging managerial responsibilities | |||||
a) | Name | Richard Jones | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Financial Officer | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc | ||||
b) | LEI | 213800U8JQHIJOS5AS09 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | ADS
| ||||
b) | Nature of the transaction | Purchase | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 2025 Aggregated price: USD6.04 | ||||
e) | Date of the transaction | 2019-04-29 | ||||
f) | Place of the transaction | XNMS | ||||
Follow the stocks
